First-pass extracted concept

autologous CAR-T therapy

Candidate: concept label1 source documents5 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

Autologous chimeric antigen receptor (CAR)-T therapies have given hope to many cancer patients whose other lines of treatment have failed.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2026MEDDOI PubMed

1 evidence snippet 5 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1costsupports2026Source 1DOI PubMed

The labor-intensive autologous CAR-T manufacturing process has led to treatment costs of roughly $500,000 per treatment.

Claim 2improvement strategysupports2026Source 1DOI PubMed

Better automation and shorter manufacturing times could reduce autologous CAR-T treatment costs.

Claim 3manufacturing constraintsupports2026Source 1DOI PubMed

Limited manufacturing capability in autologous CAR-T therapy contributes to patient waitlists and associated risk.

Claim 4process durationsupports2026Source 1DOI PubMed

Autologous CAR-T therapeutic production often takes over 4 weeks.

Claim 5systems level factorsupports2026Source 1DOI PubMed

A systems approach is needed because prior treatments, current health state including immune system and microbiota, initial cell quality, manufacturing failure, bridging and lymphodepletion therapy, and supply chain management all impact CAR-T treatment success.